{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-007952","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.828488+00:00","generated_at":"2026-06-18T01:37:47.050640+00:00","sec_items":["5.02","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cumberland Pharmaceuticals enters new employment agreements with five officers, including CEO at $675k salary","bullets":["CEO A.J. Kazimi base salary set at $675,000; effective January 1, 2023.","EVP James Herman salary $310,000; VP Todd Anthony $272,500; VP Chris Bitterman $258,500; CFO John Hamm $228,000.","All agreements are at-will with no severance for cause, death, or permanent disability.","No change-in-control or termination provisions; include non-compete, non-solicitation, confidentiality covenants.","Agreements dated March 9, 2023, effective retroactively to January 1, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-007952","json":"https://secwatch.observer/filing/0001628280-23-007952.json","markdown":"https://secwatch.observer/filing/0001628280-23-007952.md","text":"https://secwatch.observer/filing/0001628280-23-007952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023007952/0001628280-23-007952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023007952/cpix-20230315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T01:37:47.050640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}